Merck KGaA Follows Pfizer With Archemix Deal For Aptamer-Based Therapeutics
This article was originally published in PharmAsia News
Merck KGaA has committed up-front payments and research funding of up to $10 million to Archemix to collaborate on the development and commercialization of first-in-class aptamer-based drugs to treat cancer
You may also be interested in...
Aptamer therapeutics act like biologics but are chemically synthesized, according to Pfizer collaborator Archemix.
Merck signs licensing agreement for Phase II DPP-IV inhibitor with Glenmark.
Merck KGaA's acquisition of Serono, Europe's leading biotechnology company, will enhance the German drug maker's position in biologics with a portfolio generating over $2 bil. in sales in the segment